Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

• Published in: Chest Vol. 134; no. 1; p. 187
• Main Authors: Condos, Rany, Hadgiangelis, Nicos, Leibert, Eric, Jacquette, Germaine, Harkin, Timothy, Rom, William N
• Format: Journal Article
• Language: English
• Published: United States 01-07-2008
• Subjects: Acetamides - adverse effects; Acetamides - therapeutic use; Adult; Anti-Infective Agents - adverse effects; Anti-Infective Agents - therapeutic use; Child; Dose-Response Relationship, Drug; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis - drug therapy; Female; Humans; Linezolid; Male; Middle Aged; Oxazolidinones - adverse effects; Oxazolidinones - therapeutic use; Tuberculosis, Multidrug-Resistant - diagnosis; Tuberculosis, Multidrug-Resistant - drug therapy
• ISSN: 0012-3692
• DOI: 10.1378/chest.07-1988

To determine whether linezolid is safe and well tolerated in the treatment of extensively drug-resistant tuberculosis (XDR-TB).
The was conducted in a specialized tuberculosis ward for multidrug-resistant tuberculosis (MDR-TB) on the Chest Service of Bellevue Hospital Center, which is a 768-bed public hospital in New York City. Seven patients with confirmed MDR-TB or XDR-TB who were still culture positive despite appropriate directly observed therapy were treated with a regimen containing linezolid and at least one other active agent.
The linezolid-containing regimen led to sustained negative conversion of sputum cultures and radiographic improvement in all patients. Long-term therapy (longest duration of therapy, 28 months) was well tolerated in most patients. Neutropenia developed in three patients, but was reversible, and peripheral neuropathy developed in two patients.
Linezolid remains a promising possible addition to our therapeutic armamentarium against XDR-TB. Linezolid is associated with side effects that can be adequately managed. Further studies to define the mechanism of action and optimum dose should be performed.